45 results about "Annexin A2" patented technology

The invention relates to a composition for the treatment of various cancers. The composition is a vaccine containing sequences of EDB, EDA, annexin A1, endosialin, C domain of tenascin C or magic roundabout (MR) or fragments thereof as single or in a combination coupled to one or several heterologous foreign carrier molecules. The vaccine will produce antibodies that are directed against self proteins which are preferentially expressed in and around tumor vessels. The vaccine is preferably administrated together with an adjuvant.

The invention relates to application of membranin Annexin A2 of a cell Thp-1 in Angiostrongylus Cantonensis (Ac) protein Galectin-1 induced apoptosis. According to the application of the membranin Annexin A2 of the cell Thp-1 in Ac protein Galectin-1 induced apoptosis, the application provides a theoretical basis for researching applications of a pathogenesis mechanism and control of Ac and treatment of angiostrongyliasis cantonensis and provides a potential acting target, i.e., the Annexin A2 for research and development of treatment drugs; meanwhile, a foundation for research and developmentof angiostrongyliasis cantonensis treatment drugs is laid, and a target is provided for customized treatment of the Ac, so that the application has considerable market prospect and applicability.

The present invention relates to a method for the diagnosis of prostate carcinoma comprising the determination of annexin A3 (ANXA3) and / or autoantibodies against ANXA3 with a specific reagent. The method allows differentiation between benign, premalignant and malignant conditions. Further, the method has a prognostic relevance.

The invention relates to affinity short peptide for the targeted recognition of Annexin A2 and a preparation method and use of the affinity short peptide. The affinity short peptide can specifically target Annexin A2, and especially the new possibility is provided for the efficient and targeted recognition of tumor tissues and the prediction and improvement of tumor targeted therapy based on the characteristic of high expression of Annexin A2 in most tumors. The polypeptide can be used as a polypeptide molecular probe, or a tumor-directing polypeptide which can be coupled with an anti-tumor drug, is used as a target head to increase the content of the drug or drug-loaded carriers such as a nano-material, liposome and the like in cells over-expressing Annexin A2, and is added with a pharmaceutically acceptable auxiliary material or adjuvant to prepare a novel and more effective targeted anti-cancer drug. The polypeptide provided by the invention can also be prepared into an imaging agent for targeted therapy and imaging of various tumors with high expression of Annexin A2, and can also be prepared into a polypeptide inhibitor for blocking the interaction between Annexin A2 and related proteins. The polypeptide has the specific targeting effect on Annexin A2 and is high in selectivity. The peptide involved in the invention can be prepared through a chemical synthesis method, andis high in purity, small in molecular weight, high in specificity, free of immunogenicity, and safe and reliable.

The invention relates to a blood serum detection method of annexin A2 as well as a detection kit and application thereof, and particularly relates to a method for detecting HCC (Hepatocellular Carcinoma) by independently using a new marker annexin A2 or detecting the HCC by the combination of the annexin A2 and AFP (Alpha Fetal Protein) as well as the detection kit and the application thereof.

The present invention relates to a pharmaceutical composition for preventing or treating a hypertrophic scar. The present inventors acknowledged that expression inhibition of thioredoxin 5, PRRC1, S100A11, galectin 1, filamin A, eukaryotic initiation factor-5A, annexin A2 and fatty acid binding proteins 5 can be a new target for relieving and treating a hypertrophic scar. According to the present invention, the treatability of a hypertrophic scar is confirmed by producing thioredoxin 5-, PRRC1-, S100A11-, galectin 1-, filamin A-, eukaryotic initiation factor-5A-, annexin A2- and FABP5-specific siRNAs. Therefore, the knockdown of the proteins or genes coding same induces cell death in a hypertrophic scar and reduces collagen expression and thus can be highly useful for scar treatment.

Annexin A3 (ANAX3) is utilized as a biomarker for the diagnosis and prognosis of hepatocellular carcinoma (HCC) and the utilization of a monoclonal antibody against ANXA3 or antisense polynucleotide against ANXA3 mRNA for the suppression or treatment of HCC, alone or in combination with other HCC treatment. Monoclonal antibody against ANXA3 can be administered for the suppression of tumor growth, metastasis, and chemoresistance.

The invention provides non-invasive assays to reliably identify women who have or are predisposed to developing preeclampsia (PE). The method comprises measuring a level of annexin A2 (ANXA2) in a test sample obtained of a subject; and identifying the subject as having preeclampsia or at an increased risk of developing preeclampsia when the level of ANXA2 in the test sample is decreased in relation to a control sample. Methods to treat subject identified as having PE or at an increased risk of developing preeclampsia are also provided.

The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.

Provided herein is a method for diagnosing / prognosing a metastatic cancer in a subject by measuring and detecting one or more of CS-ANXA2, DCAMKL, Lgr5 or CS-ANAX2 and DCAMKL or CS-ANXA2 and Lgr5 positive circulating tumor stem cells in the subject's blood or plasma. Also provided is a method for distinguishing the presence of early stage primary cancer from advanced stage metastatic cancer in the subject by measuring and detecting AnnexinA2, CS-ANXA2 and DCAMKL−1 or Lgr5 in the blood or plasma. In addition, there is provided a method for distinguishing the presence of benign, pre-cancerous tumorous growths or cancerous tumors in the subject by measuring and detecting AnnexinA2 and circulating tumor stem cells positive for CS-ANXA2 and DCAMKL or CS-ANXA2 and Lgr5 in the blood or plasma.

Application of annexin A2 in the preparation of medicines for regulating the action of PTH. Depending on the concentration of parathyroid hormone (PTH), annexin A2 can promote or inhibit the activity of PTH on ALP (alkaline phosphatase). This effect can at least realize the two-way regulation of the osteogenesis and osteoclast function of PTH with A2, and exert the effect of treating diseases including osteoporosis. Loose treatments are more precisely targeted and adaptable.

The compositions of three kinds of cell proteins of a benign prostatic hyperplasia (BPH-1) cell, an androgen dependence prostate cancer cell LNCaP and an androgen non-dependence prostate cancer cell PC-3 are compared by adopting a dimensional electrophoresis method. Through mass spectrum analysis and database retrieval, two difference proteins of GRP78 and Annexin A2 are determined. Through Western Blotting detection on the expression of the two difference proteins in the three kinds of cells, the GRP78 and the Annexin A2 are finally determined to be used as sign proteins for detecting the prostate cancer. The invention also discloses a preparation and a use methods of the ELISA kit for detecting the prostate cancer.

The invention provides an application of thiol and nitrosylation modification of intervention annexin A2 (ANXA2) to preparation of medicines for preventing and treating atherosclerosis related blood vessel diseases, and relates to the field of the cardiovascular system. The thiol and nitrosylation modification level of ANXA2 in blood vessel tissue of animals suffering from atherosclerosis is increased. At cell level, a Cys133 site of mutation ANXA2 can restrain increase of adhesive attachment of THP1 cells and endothelial cells caused by oxLDL, and reduce mRNA level of ICAM1 and VCAM1. At animal level, the Cys133 site of mutation ANXA2 can restrain increase of atherosclerotic plaque caused by high fat diet, reduce mRNA level of ICAM1 and VCAM1 and vascular endothelial dilatation functionsand improve the atherosclerosis related blood vessel diseases. According to the application of the invention, a new preparation method of medicines for preventing and treating the atherosclerosis related blood vessel diseases is developed, and meaningful reference is provided for preventing and treating the atherosclerosis related blood vessel diseases.

The present invention relates to a biomarker for early stage ovarian cancer. Specifically, expression of the biomarker Annexin A2 is higher in the plasma of subjects with early stage ovarian cancer. Accordingly, methods of detecting early stage ovarian cancer in a subject, of identifying a subject having early stage ovarian cancer, and of determining if a subject is susceptible to developing ovarian cancer, are provided. Also provided are methods of screening candidate therapeutic agents for use in treating early stage ovarian cancer, and compositions and kits for detecting early stage ovarian cancer in a subject, for identifying a subject having early stage ovarian cancer, and for determining if a subject is susceptible to developing ovarian cancer.

Methods for treatment of a multi-drug resistant (MDR) tumor in a subject are disclosed. The methods comprise administering to the subject in need of treatment a therapeutically effective amount of ananti-mycoplasma agent and / or an agent blocking the interaction between membrane protein P37 of mycoplasma and Annexin A2 of host cells of the subject, prior to, at the same time with, or after chemotherapy. Relevant pharmaceutical compositions, kits, uses are also disclosed.